At the news
? BEARISHIMPACT 6/10 8-K filed Jul 10, 2026 at 16:02 ET
InMed Pharmaceuticals entered into Amendment No. 1 to its merger agreement with Mentari Therapeutics, clarifying deal sequencing, tax treatment, and the impact of pre-closing financing on the exchange ratio. The company also filed an S-4 registration statement for the all-stock reverse merger, expected to close in Q4 2026. The transaction effectively transforms InMed into a migraine-focused biotech (Mentari) with a $125M enterprise value for Mentari, but InMed's current shareholders face massive dilution and a reverse stock split to maintain Nasdaq listing.
- InMed (INM, $5M market cap) entered into Amendment No. 1 to merge with private biotech Mentari Therapeutics in an all-stock reverse merger.
- Mentari's equity value is set at $125,000,000, implying extreme dilution for current INM shareholders relative to the $5M market cap.
- The amendment introduces a 'Company PIPE Amendment' to allow additional pre-closing financing, which will further dilute the exchange ratio for INM holders.
- A Nasdaq Reverse Split is planned before closing to maintain listing compliance.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access